血管紧张素转化酶抑制剂能提高冠心病患者血浆中人组织激肽释放酶的含量  

ACEI may elevate plasma TK levels in CHD patients

作　　者：张琴[1] 冉晓[2] 汪道文[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院高血压研究所,武汉市430030 [2]华中科技大学同济医学院附属同济医院急诊科,武汉市430030

出　　处：《中国分子心脏病学杂志》2010年第2期102-105,共4页Molecular Cardiology of China

基　　金：国家自然科学基金(No.30430320)

摘　　要：目的探讨血管紧张素转化酶抑制剂(ACEI)对冠心病患者血浆中人组织激肽释放酶(TK)的含量的影响。方法采用生物素-亲和素双抗体夹心ELISA法检测730例冠心病患者血浆中TK的含量,其中有302例患者有ACEI服用史,428例患者无该类药物服用史。绘制TK含量的分布图并用独立样本T检验和logistic回归进行统计分析。结果冠心病患者血浆中TK含量服从正偏态分布(Skewness=0.617,SE=0.090,Kurtosis=0.774,SE=0.181)。ACEI能明显提高冠心病患者血浆TK水平(0.388±0.076mg/lvs.0.320±0.079mg/l,P<0.001;OR=3.20,95%CI2.59～3.95,P<0.001)。结论ACEI能通过提高冠心病患者血浆中TK的含量来发挥其部分心血管保护作用。Objective to explore the effect of ACEI on plasma tissue kallikrein（TK） levels in CHD patients. Methods plasma TK levels in 464 CHD patients were detected by double antibody sandwich with biotin-avidin ELISA. 162 of them were with history of ACEI taking, 302 of them were controls. We described the distribution of plasma TK and analyzed the data by Independent sample T test and unconditional logistic regression analysis. Results plasma TK in CHD patients subjected to positively skewed distribution （ Skewness = 0.617, SE = 0.090, Kurtosis = 0.774, SE = 0. 181 ）. ACEI elevated the plasma TK levels in CHD significantly（0.388 ±0.076 mg/1 vs. 0. 320 ± 0.079 mg/1, P 〈 0.001 ; OR = 3.20, 95% CI 2.59 ±3.95, P 〈 0.001 ）. Conclusion the effect of ACEI on CHD patients may partly through booting plasma TK levels.

关 键 词：ACEI 冠心病 人组织及肽释放酶 

分 类 号：R541.4[医药卫生—心血管疾病]